Panduan definitif tentang penyuntingan gen.
★
Menu
Beranda Pelajari Berita Tanya Atlas
Jelajahi Teknologi Penyakit Perawatan Uji Klinis Perusahaan Ilmuwan Gen-gen Penelitian Institusi
Di luar dunia medis Pertanian Etika Investasi Peta dunia
Pelajari & Alat Mulai di sini Glosarium A–Z Bandingkan teknologi Linimasa Daftar & Peringkat Agen AI ★ Tersimpan API
Tentang Tentang kami Metodologi Sumber Data Kebijakan Editorial Kontak Penafian

🧭 Tampilan Terpandu
Baru mengenal genetika? Kami menjelaskan setiap istilah saat kamu menjelajah, dalam bahasa yang mudah dipahami. Halaman yang sama, dengan bantuan yang sudah tersedia.

⚡ Pandangan Ahli
Kamu sudah mengenal biologinya. Cukup kontennya — ringkas dan padat, tanpa penjelasan tambahan. Ini adalah tampilan default.

Bahasa antarmuka
Mode terang

Treatment · Cancer

CTX112

An allogeneic CD19 CAR-T candidate with multiple CRISPR edits intended to make one donor's cells usable in many patients.

Phase I/II cell therapyallogeneicCAR-T
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Penjelasan sederhana

Ordinary CAR-T therapy is made individually from each patient's own cells, which takes weeks and costs a great deal. CTX112 starts from a healthy donor instead and uses several simultaneous CRISPR edits to stop the donor cells attacking the patient and to slow the patient's immune system destroying them — so one batch can serve many people, off the shelf.

Pelajari lebih dalam

CTX112 is an allogeneic anti-CD19 CAR-T candidate from CRISPR Therapeutics incorporating multiple edits to remove the endogenous T-cell receptor and MHC class I, plus potency edits intended to improve persistence. It is in trials in B-cell malignancies and has been explored in autoimmune indications; it holds FDA Regenerative Medicine Advanced Therapy designation.

Sources

Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Diseases

CancerLeukemia and Lymphoma

Clinical Trials

A Study of CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Genes

B2MTRAC

Companies

CRISPR Therapeutics
Hanya informasi edukatif Halaman ini adalah referensi, bukan nasihat medis. Status riset dan regulasi dapat berubah; periksa tanggal pembaruan terakhir di atas dan konfirmasi hal-hal penting dengan sumber primer yang tercantum.